Linked Life Data

14639619

Source:http://linkedlifedata.com/resource/pubmed/id/14639619

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-11-25
pubmed:abstractText
Because membrane type-1 matrix metalloproteinase (MT1-MMP) is expressed specifically on the angiogenic endothelium as well as tumor cells, an agent possessing the ability to bind to this molecule might be useful as a tool for active targeting of tumor angiogenic vessels. Based on the sequences of peptide substrates of MT1-MMP, which had been determined by using a phage-displayed peptide library, we examined the binding ability of peptide-modified liposomes for endothelial cells and targeting ability for tumor tissues by positron emission tomography (PET). Liposomes modified with stearoyl-Gly-Pro-Leu-Pro-Leu-Arg (GPLPLR-Lip) showed high binding ability to human umbilical vein endothelial cells and accumulated in the tumor about 4-fold more than did the unmodified liposomes. Because we reported previously that liposomalized 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (DPP-CNDAC), a hydrophobized derivative of the novel antitumor nucleoside CNDAC, strongly suppressed tumor growth when delivered in liposomes modified with another angiogenic homing peptide, we examined the antitumor activity of DPP-CNDAC entrapped in GPLPLR-Lip. DPP-CNDAC/GPLPLR-Lip showed significant tumor growth suppression compared to DPP-CNDAC/unmodified liposomes. These results suggest that DPP-CNDAC-liposomes modified with MT1-MMP-targeted peptide are useful for cancer anti-neovascular therapy (ANET), namely, tumor growth suppression by damage to angiogenic endothelial cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0020-7136
pubmed:author
pubmed:copyrightInfo
Copyright 2003 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
10
pubmed:volume
108
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
301-6
pubmed:dateRevised
2007-7-24
pubmed:meshHeading
pubmed-meshheading:14639619-Angiogenesis Inhibitors, pubmed-meshheading:14639619-Animals, pubmed-meshheading:14639619-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:14639619-Arabinonucleotides, pubmed-meshheading:14639619-Colonic Neoplasms, pubmed-meshheading:14639619-Drug Delivery Systems, pubmed-meshheading:14639619-Endothelium, Vascular, pubmed-meshheading:14639619-Humans, pubmed-meshheading:14639619-Liposomes, pubmed-meshheading:14639619-Male, pubmed-meshheading:14639619-Matrix Metalloproteinase 14, pubmed-meshheading:14639619-Matrix Metalloproteinases, Membrane-Associated, pubmed-meshheading:14639619-Metalloendopeptidases, pubmed-meshheading:14639619-Mice, pubmed-meshheading:14639619-Mice, Inbred BALB C, pubmed-meshheading:14639619-Neovascularization, Pathologic, pubmed-meshheading:14639619-Phosphatidic Acids, pubmed-meshheading:14639619-Protein Transport, pubmed-meshheading:14639619-Survival Rate, pubmed-meshheading:14639619-Treatment Outcome, pubmed-meshheading:14639619-Tumor Cells, Cultured, pubmed-meshheading:14639619-Umbilical Veins
pubmed:year
2004
pubmed:articleTitle
Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
pubmed:affiliation
Department of Medical Biochemistry and COE Program in the 21st Century, University of Shizuoka School of Pharmaceutical Sciences, Shizuoka, Japan.
pubmed:publicationType
Journal Article, Comparative Study